8-K: Carisma Therapeutics Receives Nasdaq Notice Regarding Minimum Bid Price Deficiency

Carisma Therapeutics Inc. has received a notification from Nasdaq that it is not in compliance with the minimum bid price requirement of $1.00 per share.

Summary

• Carisma Therapeutics Inc. received a notice from Nasdaq on January 6, 2025, stating that it does not meet the minimum bid price requirement of $1.00 per share, as per Nasdaq Listing Rule 5450(a)(1).
• The notice is not an indication of imminent delisting and does not currently affect the trading of Carisma Therapeutics' securities on The Nasdaq Global Market under the symbol CARM.
• Carisma Therapeutics has a 180-day compliance period, until July 7, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
• If compliance is not achieved within the initial 180-day period, Carisma Therapeutics may be eligible for an additional 180-day period by transferring its listing to The Nasdaq Capital Market, provided it meets other listing requirements.
• To effect such a transfer, the Company would also need to pay an application fee to Nasdaq and provide written notice of the Company's intention to cure the deficiency during the additional compliance period by effecting a reverse stock split, if necessary.
• Nasdaq will review the company's ability to cure the deficiency, and if it concludes that the company will not be able to do so, or if the company does not submit a transfer application or meet other listing standards for The Nasdaq Capital Market, Nasdaq could provide notice that the company's securities will become subject to delisting.
• Carisma Therapeutics intends to monitor its stock price and consider available options to regain compliance.
• The company has the right to appeal any delisting decision to a Nasdaq Hearing Panel.

Sentiment

Score: 4

Explanation: The news is negative as it indicates financial distress and potential delisting, but the company has time to rectify the situation.

Positives

• The notice is not an indication of imminent delisting, and the company's securities continue to trade on The Nasdaq Global Market.
• Carisma Therapeutics has a 180-day period to regain compliance, providing an opportunity to improve its stock price.
• The option to transfer to The Nasdaq Capital Market offers a potential pathway for an additional compliance period.

Negatives

• Carisma Therapeutics' stock price has fallen below the required minimum bid price of $1.00 per share.
• Failure to regain compliance could lead to delisting from The Nasdaq Global Market.

Risks

• There is no guarantee that Carisma Therapeutics will be able to regain compliance with the minimum bid price rule within the given timeframe.
• Delisting from The Nasdaq Global Market could negatively impact the company's stock price and investor confidence.
• The company may need to implement measures such as a reverse stock split, which could further dilute shareholder value.

Future Outlook

The company intends to monitor the closing bid price of its common stock and consider its available options to regain compliance with the Bid Price Rule; however, there is no assurance that the Company will achieve such expectations, including regaining compliance with the Bid Price Rule during any compliance period or in the future, otherwise meeting Nasdaq compliance standards, being granted by Nasdaq any relief from delisting as necessary, or ultimately meeting applicable Nasdaq requirements for any such relief.

Management Comments

• The Company intends to monitor the closing bid price of its common stock and consider its available options to regain compliance with the Bid Price Rule.

Industry Context

Many biotech companies, especially those in the early stages of development, can face challenges in maintaining stock prices above the Nasdaq minimum bid price due to the inherent risks and uncertainties associated with drug development and regulatory approvals.

Comparison to Industry Standards

• Other biotech companies that have faced similar Nasdaq compliance issues include [hypothetical company A] and [hypothetical company B], which both received deficiency notices for failing to meet the minimum bid price requirement.
• [Hypothetical company A] successfully regained compliance through a combination of positive clinical trial results and investor relations efforts.
• [Hypothetical company B] ultimately underwent a reverse stock split to increase its share price and maintain its Nasdaq listing.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is unable to regain compliance and is delisted.
• Employees may face uncertainty regarding the company's future if the delisting risk persists.

Next Steps

• Carisma Therapeutics will monitor its stock price.
• Carisma Therapeutics will consider available options to regain compliance with the Bid Price Rule.
• Carisma Therapeutics may need to submit a plan to Nasdaq outlining how it intends to regain compliance.

Key Dates